Related Experiment Video
Updated: Apr 26, 2026
Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells
Published on: July 30, 2020
Identification of new novel scaffold for Aurora A inhibition by pharmacophore modeling and virtual screening
Sayalee R Chavan1, Radha Charan Dash, M Sarwar Alam
1CSIR Unit for Research and Development of Information Products, "Jopasana", 85/1, Paud Road, Kothrud, Pune, 411038, India, sayalee@urdip.res.in.
Abstract:
Aurora kinases belong to family of highly conserved serine/threonine protein kinases that are involved in diverse cell cycle events and play a major role in regulation of cell division. Abnormal expression of Aurora kinases may lead to cancer; hence, these are considered as a potential target in cancer treatment. In this research article, we identified three novel Aurora A inhibitors using modern computational tools. A four-point common 3D pharmacophore hypothesis of Aurora A (AurA) inhibitors was developed using a diverse set of 55 thienopyrimidine derivatives. A three-dimensional quantitative structure-activity relationship (3D-QSAR) study was carried out using atom-based alignment of diverse set of 55 molecules to evaluate the structure- activity relationships. Docking and 3D-QSAR studies were performed with the 3D structure of AurA to evaluate the generated pharmacophore. The pharmacophore model and 3D-QSAR results complemented the results of our docking study. The pharmacophore hypothesis, which yields the best results, was used to screen the Zinc 'clean drug-like' database. Various database filters such as 3D-arrangement of pharmacophoric features, predicted activity and binding interaction score were used to retrieve hits having potential AurA inhibition activity.
Insights
Researchers identified novel Aurora A inhibitors for cancer treatment using computational methods. This study developed a pharmacophore model and 3D-QSAR to screen for potential drug candidates targeting Aurora A kinase.
Area of Science:
- Medicinal Chemistry
- Computational Biology
- Molecular Pharmacology
Background:
- Aurora kinases are crucial serine/threonine protein kinases regulating cell division.
- Aberrant Aurora kinase expression is linked to cancer development, making them promising therapeutic targets.
- Thienopyrimidine derivatives have shown potential as Aurora kinase inhibitors.
Purpose of the Study:
- To identify novel inhibitors of Aurora A kinase using computational approaches.
- To develop a robust pharmacophore model and conduct 3D-QSAR studies for Aurora A inhibitors.
- To screen a large chemical database for potential drug candidates targeting Aurora A kinase.
Main Methods:
- Development of a four-point 3D pharmacophore hypothesis for Aurora A inhibitors based on 55 thienopyrimidine derivatives.
- Application of atom-based 3D-QSAR to analyze structure-activity relationships.
- Molecular docking studies using the 3D structure of Aurora A kinase.
- Screening of the Zinc 'clean drug-like' database using the validated pharmacophore model.
Main Results:
- A validated four-point pharmacophore model for Aurora A inhibitors was successfully generated.
- 3D-QSAR and docking studies confirmed the pharmacophore model's efficacy.
- Database screening yielded potential hits with predicted Aurora A inhibition activity.
Conclusions:
- The study successfully identified novel Aurora A inhibitors through integrated computational strategies.
- The developed pharmacophore model and 3D-QSAR provide a valuable framework for designing future Aurora A inhibitors.
- This research offers promising lead compounds for developing new cancer therapeutics targeting Aurora A kinase.
